GAL and hepatocellular carcinoma: Employing a similarly galactosylated PLL system, Jing et al. explored a novel approach using Gal–PLL (Mw = 48 kDa, Gal/PLL = 24:1) to enhance the targeted delivery of c-myc antisense oligodeoxynucleotides to hepatocellular carcinoma (HCC) cells via ultrasound-targeted microbubble destruction [70].